1. DeLellis RA, Lloyd RV, Heitz PU et al. World Health Organization (2004) WHO Classification of Tumours, Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press, 2004.
2. Joel T, Goswin Y, Herbert Chen et al. Pheochromocytoma: Current Approaches and Future Directions. Oncologist 2008.
3. Чазова И.Е. и др. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов: Диагностика и лечение артериальной гипертензии. Кардиоваскулярная терапия и профилактика. 2008; 7 (6). Прил. 2.
4. Pacak K, Lenders JWM, Eisenhofer G. 2007 Introduction. In: pheochromocytoma diagnosis, localization and treatment. Malden, MA: Blackwell, p. 1–2.
5. Elder EE, Elder G, Larsson C. Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol 2005; 89: 193–201.
6. Amar L, Servais A, Gimenez-Roqueplo AP et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005; 90: 2110–6.
7. Pacak K, Eisenhofer G, Ahlman H et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007; 3: 92–102.
8. Юкина М.Ю., Трошина Е.А., Бельцевич Д.Г. и др. Феохромоцитома/параганглиома: клинико-генетические аспекты. Проблемы эндокринологии. 2013; 3: 19–26.
9. Kaplan NM. Pheochromocytoma with a preface about incidental adrenal masses. In: Kaplan’s clinical hypertension. Philadelphia, PA: Lippincott, Williams & Wilkins, 2006; p. 389–433.
10. Mittendorf EA, Evans DB, Lee JE, Perrier ND. Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment. Hematol Oncol Clin North Am 2007; 21: 509–25.
11. Sawka AM, Jaeschke R, Singh RJ, Young WF. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88: 553–8.
12. Václavík J, Stejskal D, Lacnák B et al. Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens 2007; 25: 1427–31.
13. Kloos RT et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19 (6): 565–612.
14. Трошина Е.А., Юкина М.Ю., Бельцевич Д.Г. Симптоматическая артериальная гипертензия при феохромоцитоме (клиническое течение, терапия). Особенности проведения теста с Клонидином. Cons. Med. 2013; 4 (15): 75–9.
15. Giovanella L. Serum chromogranin-A assay in differential diagnosis of incidentally discovered adrenal masses. Anticancer Res 2005; 25: 1547–50.
16. Pacak K, Lenders JWM, Eisenhofer G. Current trends in biochemical diagnosis of pheochromocytoma. In: pheochromocytoma, diagnosis, localization and treatment. Malden, MA: Blackwell, 2007; p. 72–92.
17. Shulkin BL, Ilias I, Sisson JC, Pacak K. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 2006; 1073: 374–82.
18. Kaji P, Carrasquillo JA, Linehan WM et al. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol 2007; 156: 483–7.
19. Ilias I, Chen CC, Carrasquillo JA et al. Comparison of 6-[18F]-fluorodopamine positron emission tomography to [123I]-metaiodobenzylguanidine and [111In]-pentetreotide scintigraphy in the localization of non-metastatic and metastatic pheochromocytoma. J Nucl Med 2008; 49: 1613–9.
20. Khorram-Manesh A, Ahlman H, Nilsson O et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med 2005; 258: 55–66.
21. Mannelli M. Management and treatment of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 2006; 1073: 405–16.
22. Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2002; 16: 359–69. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007; 92: 4069–79.
23. Sisson JC, Shulkin BL, Esfandiari NH. Courses of malignant pheochromocytoma: Implications for therapy. Ann N Y Acad Sci 2006; 1073: 505–11.
24. Loh KC, Fitzgerald PA, Matthay KK et al. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131IMIBG): A comprehensive review of 116 reported patients. J Endocrinol Invest 1997; 20: 648–58.
25. Kaltsas GA, Papadogias D, Makras P et al. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005; 12: 683–99.
26. Nakane M, Takahashi S, Sekine I et al. Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline. Ann Oncol 2003; 14: 1449–51.
27. Chrisoulidou A, Kaltsas G, Ilias I et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007; 14: 569–85.
28. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003; 3: 377–83.
29. Kappes A, Vaccaro A, Kunnimalaiyaan M et al. Lithium ions: A novel treatment for pheochromocytomas and paragangliomas. Surgery 2007; 141: 161–5; discussion 165.
30. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002; 26: 551–66.
31. Brouwers FM, Eisenhofer G, Tao JJ et al. High frequency of SDHB герминальной mutations in patients with malignant catecholamine-producing paragangliomas: Implications for genetic testing. J Clin Endocrinol Metab 2006; 91: 4505–9.
32. Joel T, Goswin Y, Herbert Chen et al. Pheochromocytoma: current approaches and future directions the oncologist 2008; 13 (7): 779–93.

М.Ю.Юкина, Е.А.Трошина

ФГБУ Эндокринологический научный центр Минздрава России, Москва